Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Murali, K. & Banerjee, S. (2019). Let’s address burnout in oncologists and reimagine the way we work. Nature reviews clinical oncology, Vol.16 (1), pp. 1-2.

Castellani, F., Nganga, E.C., Dumas, L., Banerjee, S. & Rockall, A.G. (2019). Imaging in the pre-operative staging of ovarian cancer. Abdominal radiology, Vol.44 (2), pp. 685-696.

Banerjee, S. (2019). Reply to ‘Physician burnout: let’s avoid unsubstantiated claims’. Nature reviews clinical oncology, Vol.16 (2), pp. 137-137.

Liposits, G., Loh, K.P., Soto-Perez-de-Celis, E., Dumas, L., Battisti, N.M., Kadambi, S., Baldini, C., Banerjee, S. & Lichtman, S.M. (2019). PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper. Journal of geriatric oncology, Vol.10 (2), pp. 337-345.

Fabbro, M., Moore, K.N., Dørum, A., Tinker, A.V., Mahner, S., Bover, I., Banerjee, S., Tognon, G., Goffin, F., Shapira-Frommer, R., et al. (2019). Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Gynecologic oncology, Vol.152 (3), pp. 560-567.

Khalique, S., Lord, C.J., Banerjee, S. & Natrajan, R. (2019). Translational genomics of ovarian clear cell carcinoma. Seminars in cancer biology, .

Banerjee, S., Oza, A.M., Birrer, M.J., Hamilton, E.P., Hasan, J., Leary, A., Moore, K.N., Mackowiak-Matejczyk, B., Pikiel, J., Ray-Coquard, I., et al. (2018). Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Annals of oncology, Vol.29 (4), pp. 917-923.

Prager, G.W., Braga, S., Bystricky, B., Qvortrup, C., Criscitiello, C., Esin, E., Sonke, G.S., Martínez, G.A., Frenel, J.-., Karamouzis, M., et al. (2018). Global cancer control: responding to the growing burden, rising costs and inequalities in access. Esmo open, Vol.3 (2), pp. e000285-e000285.

Stewart, J., George, A. & Banerjee, S. (2018). Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation. Expert review of anticancer therapy, Vol.18 (10), pp. 947-958.

Oza, A., Kaye, S., Van Tornout, J., Sessa, C., Gore, M., Naumann, R.W., Hirte, H., Colombo, N., Chen, J., Gorla, S., et al. (2018). Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. Gynecologic oncology, Vol.149 (2), pp. 275-282.

Moore, K.N., Vergote, I., Oaknin, A., Colombo, N., Banerjee, S., Oza, A., Pautier, P., Malek, K. & Birrer, M.J. (2018). FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Future oncology, Vol.14 (17), pp. 1669-1678.

Khalique, S., Naidoo, K., Attygalle, A.D., Kriplani, D., Daley, F., Lowe, A., Campbell, J., Jones, T., Hubank, M., Fenwick, K., et al. (2018). Optimised ARID1A immunohistochemistry is an accurate predictor ofARID1Amutational status in gynaecological cancers. The journal of pathology: clinical research, Vol.4 (3), pp. 154-166.

Murali, K. & Banerjee, S. (2018). Burnout in oncologists is a serious issue: What can we do about it?. Cancer treatment reviews, Vol.68, pp. 55-61.

Oza, A.M., Matulonis, U.A., Malander, S., Hudgens, S., Sehouli, J., del Campo, J.M., Berton-Rigaud, D., Banerjee, S., Scambia, G., Berek, J.S., et al. (2018). Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. The lancet oncology, Vol.19 (8), pp. 1117-1125.

Banerjee, S., Dafni, U., Allen, T., Arnold, D., Curigliano, G., Garralda, E., Garassino, M.C., Haanen, J., Hofstädter-Thalmann, E., Robert, C., et al. (2018). Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. Esmo open, Vol.3 (6), pp. e000422-e000422.  show abstract

Hofstädter-Thalmann, E., Dafni, U., Allen, T., Arnold, D., Banerjee, S., Curigliano, G., Garralda, E., Garassino, M.C., Haanen, J., Robert, C., et al. (2018). Report on the status of women occupying leadership roles in oncology. Esmo open, Vol.3 (6), pp. e000423-e000423.  show abstract

Orbegoso, C., Murali, K. & Banerjee, S. (2018). The current status of immunotherapy for cervical cancer. Reports of practical oncology & radiotherapy, Vol.23 (6), pp. 580-588.

Heindl, A., Khan, A.M., Rodrigues, D.N., Eason, K., Sadanandam, A., Orbegoso, C., Punta, M., Sottoriva, A., Lise, S., Banerjee, S., et al. (2018). Microenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticity. Nature communications, Vol.9 (1).

Basu, B., Krebs, M.G., Sundar, R., Wilson, R.H., Spicer, J., Jones, R., Brada, M., Talbot, D.C., Steele, N., Ingles Garces, A.H., et al. (2018). Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer. Ann oncol, .  show abstract

Murali, K., Makker, V., Lynch, J. & Banerjee, S. (2018). From Burnout to Resilience: An Update for Oncologists. American society of clinical oncology educational book, (38), pp. 862-872.

Moore, K., Colombo, N., Scambia, G., Kim, B.-., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G.S., et al. (2018). Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. New england journal of medicine, Vol.379 (26), pp. 2495-2505.

Banerjee, S., Califano, R., Corral, J., de Azambuja, E., De Mattos-Arruda, L., Guarneri, V., Hutka, M., Jordan, K., Martinelli, E., Mountzios, G., et al. (2017). Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey. Annals of oncology, Vol.28 (7), pp. 1590-1596.

Banerjee, S., Preusser, M., Tabernero, J. & Strijbos, M. (2017). Reply to the letter to the editor ‘Can we trust burnout research?’ by Bianchi et al. Annals of oncology, Vol.28 (10), pp. 2625-2626.

Khalique, S. & Banerjee, S. (2017). Nintedanib in ovarian cancer. Expert opinion on investigational drugs, Vol.26 (9), pp. 1073-1081.

McLachlan, J., Boussios, S., Okines, A., Glaessgen, D., Bodlar, S., Kalaitzaki, R., Taylor, A., Lalondrelle, S., Gore, M., Kaye, S., et al. (2017). The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer. Clinical oncology, Vol.29 (3), pp. 153-160.

George, A., Banerjee, S. & Kaye, S. (2017). Olaparib and somatic BRCA mutations. Oncotarget, Vol.8 (27).

Dougherty, B.A., Lai, Z., Hodgson, D.R., Orr, M.C., Hawryluk, M., Sun, J., Yelensky, R., Spencer, S.K., Robertson, J.D., Ho, T.W., et al. (2017). Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. Oncotarget, Vol.8 (27).

Dolly, S.O., Migali, C., Tunariu, N., Della-Pepa, C., Khakoo, S., Hazell, S., de Bono, J.S., Kaye, S.B. & Banerjee, S. (2017). Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. Esmo open, Vol.2 (1), pp. e000101-e000101.

George, A., Kaye, S. & Banerjee, S. (2017). Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nature reviews clinical oncology, Vol.14 (5), pp. 284-296.

George, A., Kristeleit, R., Rafii, S., Michie, C.O., Bowen, R., Michalarea, V., van Hagen, T., Wong, M., Rallis, G., Molife, L.R., et al. (2017). Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. European journal of cancer, Vol.76, pp. 52-59.

Capoluongo, E., Ellison, G., López-Guerrero, J.A., Penault-Llorca, F., Ligtenberg, M.J., Banerjee, S., Singer, C., Friedman, E., Markiefka, B., Schirmacher, P., et al. (2017). Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Seminars in oncology, Vol.44 (3), pp. 187-197.

Pujade-Lauraine, E., Ledermann, J.A., Selle, F., Gebski, V., Penson, R.T., Oza, A.M., Korach, J., Huzarski, T., Poveda, A., Pignata, S., et al. (2017). Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. The lancet oncology, Vol.18 (9), pp. 1274-1284.

Banerjee, S. (2017). Bevacizumab in cervical cancer: a step forward for survival. The lancet, Vol.390 (10103), pp. 1626-1628.

George, A., McLachlan, J., Tunariu, N., Della Pepa, C., Migali, C., Gore, M., Kaye, S. & Banerjee, S. (2017). The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole. Bmc cancer, Vol.17 (1).

Orbegoso, C., Marquina, G., George, A. & Banerjee, S. (2017). The role of Cediranib in ovarian cancer. Expert opinion on pharmacotherapy, Vol.18 (15), pp. 1637-1648.

Rafii, S., Gourley, C., Kumar, R., Geuna, E., Ang, J.E., Rye, T., Chen, L.-., Shapira-Frommer, R., Friedlander, M., Matulonis, U., et al. (2017). Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Oncotarget, Vol.8 (29).

Phelan, C.M., Kuchenbaecker, K.B., Tyrer, J.P., Kar, S.P., Lawrenson, K., Winham, S.J., Dennis, J., Pirie, A., Riggan, M.J., Chornokur, G., et al. (2017). Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat genet, Vol.49, pp. 680-691.  show abstract

Heath, O.M., van Beekhuizen, H.J., Nama, V., Kolomainen, D., Nobbenhuis, M.A., Ind, T.E., Sohaib, S.A., Lofts, F.J., Heenan, S., Gore, M., et al. (2016). Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases. Thrombosis research, Vol.137, pp. 30-35.

McLachlan, J., Lima, J.P., Dumas, L. & Banerjee, S. (2016). Targeted agents and combinations in ovarian cancer: where are we now?. Expert review of anticancer therapy, Vol.16 (4), pp. 441-454.

McLachlan, J. & Banerjee, S. (2016). Olaparib for the treatment of epithelial ovarian cancer. Expert opinion on pharmacotherapy, Vol.17 (7), pp. 995-1003.

Moschetta, M., George, A., Kaye, S.B. & Banerjee, S. (2016). BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Annals of oncology, Vol.27 (8), pp. 1449-1455.

McLachlan, J., Gore, M. & Banerjee, S. (2016). Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary. Pharmacogenomics, Vol.17 (12), pp. 1353-1363.

McLachlan, J., George, A. & Banerjee, S. (2016). The Current Status of PARP Inhibitors in Ovarian Cancer. Tumori journal, Vol.102 (5), pp. 433-440.

Dittrich, C., Kosty, M., Jezdic, S., Pyle, D., Berardi, R., Bergh, J., El-Saghir, N., Lotz, J.-., Österlund, P., Pavlidis, N., et al. (2016). ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. Esmo open, Vol.1 (5), pp. e000097-e000097.

Dumas, L., Ring, A., Butler, J., Kalsi, T., Harari, D. & Banerjee, S. (2016). Improving outcomes for older women with gynaecological malignancies. Cancer treatment reviews, Vol.50, pp. 99-108.

Vergote, I., Banerjee, S., Gerdes, A.-., van Asperen, C., Marth, C., Vaz, F., Ray-Coquard, I., Stoppa-Lyonnet, D., Gonzalez-Martin, A., Sehouli, J., et al. (2016). Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. European journal of cancer, Vol.69, pp. 127-134.

Friedlander, M., Banerjee, S., Mileshkin, L., Scott, C., Shannon, C. & Goh, J. (2016). Practical guidance on the use of olaparib capsules as maintenance therapy for women withBRCAmutations and platinum-sensitive recurrent ovarian cancer. Asia-pacific journal of clinical oncology, Vol.12 (4), pp. 323-331.

Morgan, G., Lambertini, M., Kourie, H.R., Amaral, T., Argiles, G., Banerjee, S., Cardone, C., Corral, J., De Mattos-Arruda, L., Öztürk, A., et al. (2016). Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). Esmo open, Vol.1 (6), pp. e000107-e000107.

Percival, N., George, A., Gyertson, J., Hamill, M., Fernandes, A., Davies, E., Rahman, N. & Banerjee, S. (2016). The integration of BRCA testing into oncology clinics. British journal of nursing, Vol.25 (12), pp. 690-694.

Meeks, H.D., Song, H., Michailidou, K., Bolla, M.K., Dennis, J., Wang, Q., Barrowdale, D., Frost, D., Embrace, , McGuffog, L., et al. (2016). BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J natl cancer inst, Vol.108.  show abstract

McLachlan, J. & Banerjee, S. (2015). Pazopanib in ovarian cancer. Expert review of anticancer therapy, Vol.15 (9), pp. 995-1005.

Younger, E., Okines, A.F., Tan, D.S., Anandappa, G., Tokaca, N., Thomas, B., Gore, M., Kaye, S. & Banerjee, S. (2015). CARBOPLATIN DESENSITISATION EXPERIENCE IN CLINICAL PRACTICE. International journal of gynecological cancer, Vol.25 (9), pp. 508-508.

Lima, J., Mclachlan, J., della Peppa, C., Nobbenhuis, M., Gore, M., Kaye, S. & Banerjee, S. (2015). CLINICAL OUTCOMES OF LOW GRADE SEROUS OVARIAN CARCINOMA: A TWENTY FIVE YEAR RETROSPECTIVE CASE SERIES OF THE ROYAL MARSDEN EXPERIENCE. International journal of gynecological cancer, Vol.25 (9), pp. 1420-1421.

Kolomainen, D.F., Butler, J., Barton, D.P., Ind, T.E., Nobbenhuis, M.A., Lalondrelle, S., Taylor, A., Shepherd, J.H., Gore, M.E., Kaye, S.B., et al. (2015). IS THERE A SURVIVAL BENEFIT FOR PATIENTS WHO RECEIVE POST-OPERATIVE ADJUVANT CHEMOTHERAPY FOLLOWING SECONDARY CYTOREDUCTIVE SURGERY (SCRS) FOR RECURRENT EPITHELIAL OVARIAN CANCER (EOC)?. International journal of gynecological cancer, Vol.25 (9), pp. 1407-1407.

Heath, O., van Beekhuizen, H., Kolomainen, D., Nama, V., Nobbenhuis, M., Ind, T., Sohaib, A., Lofts, F., Heenan, S., Gore, M., et al. (2015). SYMPTOMATIC AND ASYMPTOMATIC VENOUS THROMBOEMBOLISM AT TIME OF DIAGNOSIS OF PRIMARY OVARIAN CANCER. International journal of gynecological cancer, Vol.25 (9), pp. 387-387.

Seifert, H., Georgiou, A., Alexander, H., McLachlan, J., Bodla, S., Kaye, S., Barton, D., Nobbenhuis, M., Gore, M. & Banerjee, S., et al. (2015). Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC). Gynecologic oncology, Vol.139 (2), pp. 216-220.

Symonds, R.P., Gourley, C., Davidson, S., Carty, K., McCartney, E., Rai, D., Banerjee, S., Jackson, D., Lord, R., McCormack, M., et al. (2015). Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. The lancet oncology, Vol.16 (15), pp. 1515-1524.

Seifert, H., Georgiou, A., Alexander, H., McLachlan, J., Bodla, S., Kaye, S., Barton, D., Nobbenhuis, M., Gore, M. & Banerjee, S., et al. (2015). Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC). Gynecologic oncology, Vol.139 (2), pp. 216-220.

Lan, C., Heindl, A., Huang, X., Xi, S., Banerjee, S., Liu, J. & Yuan, Y. (2015). Quantitative histology analysis of the ovarian tumour microenvironment. Scientific reports, Vol.5 (1).

Boussios, S., Attygalle, A., Hazell, S., Moschetta, M., Mclachlan, J., Okines, A. & Banerjee, S. (2015). Malignant Ovarian Germ Cell Tumors in Postmenopausal Patients: The Royal Marsden Experience and Literature Review. Anticancer research, Vol.35 (12), pp. 6713-6722.

Banerjee, S. & Stanway, S. (2015). Problem solving in acute oncology. British journal of cancer, Vol.113 (12), pp. 1744-1745.

Boussios, S., Moschetta, M., McLachlan, J. & Banerjee, S. (2015). Bleomycin-Induced Flagellate Erythema in a Patient Diagnosed with Ovarian Yolk Sac Tumor. Case reports in oncological medicine, Vol.2015, pp. 1-2.  show abstract

Syrios, J., Banerjee, S. & Kaye, S.B. (2014). Advanced Epithelial Ovarian Cancer: From Standard Chemotherapy to Promising Molecular Pathway Targets - Where Are we Now?. Anticancer research, Vol.34 (5), pp. 2069-2077.

Califano, R., Karamouzis, M.V., Banerjee, S., de Azambuja, E., Guarneri, V., Hutka, M., Jordan, K., Kamposioras, K., Martinelli, E., Corral, J., et al. (2014). Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee. Lung cancer, Vol.85 (1), pp. 74-80.  show abstract

Nobbenhuis, M.A., Lalondrelle, S., Larkin, J. & Banerjee, S. (2014). Management of melanomas of the gynaecological tract. Curr opin oncol, Vol.26 (5), pp. 508-513.  show abstract

Penson, R.T., Moore, K.M., Fleming, G.F., Braly, P., Schimp, V., Nguyen, H., Matulonis, U.A., Banerjee, S., Haluska, P., Gore, M., et al. (2014). A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol oncol, Vol.134 (3), pp. 478-485.  show abstract

George, A., Smith, F., Cloke, V., Gore, M.E., Hanson, H., Banerjee, S. & Rahman, N. (2014). 881PDIMPLEMENTATION OF ROUTINE BRCA GENE TESTING OF OVARIAN CANCER (OC) PATIENTS AT ROYAL MARSDEN HOSPITAL. Annals of oncology, Vol.25 (suppl_4), pp. iv307-iv307.

Canario, R., Lima, J.P., Migali, C., Tunariu, N., George, A., Kaye, S.B., Gore, M.E. & Banerjee, S. (2014). 877PDCLINICAL OUTCOMES OF RECURRENT OVARIAN GRANULOSA CELL TUMOURS TREATED WITH LETROZOLE: A 10-YEAR RETROSPECTIVE CASE-SERIES OF THE ROYAL MARSDEN HOSPITAL. Annals of oncology, Vol.25 (suppl_4), pp. iv305-iv306.

McNeish, I.A., Ledermann, J.A., Webber, L., James, L., Kaye, S.B., Hall, M., Hall, G., Clamp, A., Earl, H., Banerjee, S., et al. (2014). A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†. Ann oncol, Vol.25 (10), pp. 1988-1995.  show abstract

Thway, K., Hazell, S., Banerjee, S. & Fisher, C. (2014). Rhabdomyosarcoma with pseudolipoblasts arising in ovarian carcinosarcoma: a distinctive postchemotherapy morphologic variant mimicking pleomorphic liposarcoma. Case rep pathol, Vol.2014, p. 238545.  show abstract

Della Pepa, C. & Banerjee, S. (2014). Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer. Onco targets ther, Vol.7, pp. 1025-1032.  show abstract

Banerjee, S. & Kaye, S.B. (2013). New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin cancer res, Vol.19 (5), pp. 961-968.  show abstract

Weigel, M.T., Banerjee, S., Arnedos, M., Salter, J., A'Hern, R., Dowsett, M. & Martin, L.A. (2013). Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer. Ann oncol, Vol.24 (1), pp. 126-133.  show abstract

Ang, J.E., Gourley, C., Powell, C.B., High, H., Shapira-Frommer, R., Castonguay, V., De Greve, J., Atkinson, T., Yap, T.A., Sandhu, S., et al. (2013). Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin cancer res, Vol.19 (19), pp. 5485-5493.  show abstract

Banerjee, S., Rustin, G., Paul, J., Williams, C., Pledge, S., Gabra, H., Skailes, G., Lamont, A., Hindley, A., Goss, G., et al. (2013). A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Ann oncol, Vol.24 (3), pp. 679-687.  show abstract

Tan, D.S., Yap, T.A., Hutka, M., Roxburgh, P., Ang, J., Banerjee, S., Grzybowska, E., Gourley, C., Gore, M.E. & Kaye, S.B., et al. (2013). Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. Eur j cancer, Vol.49 (6), pp. 1246-1253.  show abstract

Banerjee, S. & Gore, M. (2013). Personalized therapy in gynecological cancer: a reality in clinical practice?. Curr oncol rep, Vol.15 (3), pp. 201-203.

Miller, R.E. & Banerjee, S. (2013). The current state of pemetrexed in ovarian cancer. Expert opin investig drugs, Vol.22 (9), pp. 1201-1210.  show abstract

Jenkins, V., Catt, S., Banerjee, S., Gourley, C., Montes, A., Solis-Trapala, I., Monson, K. & Fallowfield, L. (2013). Patients' and oncologists' views on the treatment and care of advanced ovarian cancer in the UK: results from the ADVOCATE study. British journal of cancer, Vol.108 (11), pp. 2264-2271.

Lopez, J., Banerjee, S. & Kaye, S.B. (2013). New developments in the treatment of ovarian cancer--future perspectives. Ann oncol, Vol.24 Suppl 10, pp. x69-x76.  show abstract

Weigelt, B. & Banerjee, S. (2012). Molecular targets and targeted therapeutics in endometrial cancer. Current opinion in oncology, Vol.24 (5), pp. 554-563.

Banerjee, S. & Kaye, S. (2012). Progression-free survival versus overall survival in ovarian cancer: where are we now?. Curr oncol rep, Vol.14 (6), pp. 483-485.

Banerjee, S. & Gore, M. (2012). Recent advances in systemic treatments for ovarian cancer. Cancer imaging, Vol.12, pp. 305-309.  show abstract

Banerjee, S. & Kaye, S.B. (2012). Gynecological cancer: First-line bevacizumab for ovarian cancer--new standard of care?. Nat rev clin oncol, Vol.9 (4), pp. 194-196.

Banerjee, S. (2011). The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer. Steroids, Vol.76 (8), pp. 807-811.  show abstract

Banerjee, S. & Kaye, S. (2011). The role of targeted therapy in ovarian cancer. Eur j cancer, Vol.47 Suppl 3, pp. S116-S130.  show abstract

Banerjee, S. & Kaye, S. (2011). PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Curr oncol rep, Vol.13 (6), pp. 442-449.  show abstract

Sanfilippo, R., Grosso, F., Jones, R.L., Banerjee, S., Pilotti, S., D'Incalci, M., Tos, A.P., Raspagliesi, F., Judson, I. & Casali, P.G., et al. (2011). Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers. Gynecologic oncology, Vol.123 (3), pp. 553-556.

Weigel, M.T., Banerjee, S., A'Hern, R., Arnedos, M., Ghazoui, Z., Dunbier, A.K., Dowsett, M. & Martin, L.-. (2011). P4-01-01: Preclinical and Clinical Studies of Estrogen Deprivation Support the PDGF/Abl Pathway as a Novel Therapeutic Target for Overcoming Resistance. Poster session abstracts, .

Banerjee, S.N., Mitchell, S., Al-Muderis, O., Pennert, K., Dunlop, A., Propert-Lewis, C., Judson, I.R. & Scurr, M.R. (2011). The Royal Marsden Hospital experience of trabectedin in patients with advanced soft tissue sarcoma (STS): Toxicity and efficacy in a nonselected group. Journal of clinical oncology, Vol.29 (15).

Harb, W.A., Sessa, C., Hirte, H.W., Kaye, S.B., Simantov, R., Banerjee, S.N., Christinat, A., Sternberg, D.W., Singh, M., Light, R., et al. (2011). A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors. Journal of clinical oncology, Vol.29 (15).

Banerjee, S.N., Mitchell, S., Al-Muderis, O., Pennert, K., Dunlop, A., Propert-Lewis, C., Judson, I.R. & Scurr, M.R. (2011). The Royal Marsden Hospital experience of trabectedin in patients with advanced soft tissue sarcoma (STS): Toxicity and efficacy in a nonselected group. J clin oncol, Vol.29 (15_suppl), p. e20507.  show abstract

Banerjee, S. (2010). Becoming a new consultant: how to make it work for you. Clin med (lond), Vol.10 (1), pp. 41-42.

Banerjee, S. & Cunningham, D. (2010). Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions. Clin colorectal cancer, Vol.9 Suppl 1, pp. S28-S35.  show abstract

Banerjee, S., Kaye, S.B. & Ashworth, A. (2010). Making the best of PARP inhibitors in ovarian cancer. Nat rev clin oncol, Vol.7 (9), pp. 508-519.  show abstract

Banerjee, S. & Smith, I.E. (2010). Management of small HER2-positive breast cancers. Lancet oncol, Vol.11 (12), pp. 1193-1199.  show abstract

Banerjee, S., A'Hern, R., Detre, S., Littlewood-Evans, A.J., Evans, D.B., Dowsett, M. & Martin, L.A. (2010). Biological Evidence for Dual Antiangiogenic-Antiaromatase Activity of the VEGFR Inhibitor PTK787/ZK222584 In vivo. Clin cancer res, Vol.16 (16), pp. 4178-4187.  show abstract

Banerjee, S., A'Hern, R., Detre, S., Littlewood-Evans, A.J., Evans, D.B., Dowsett, M. & Martin, L.-. (2010). Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo. Clin cancer res, Vol.16 (16), pp. 4178-4187.  show abstract

Banerjee, S., Zvelebil, M., Furet, P., Mueller-Vieira, U., Evans, D.B., Dowsett, M. & Martin, L.-. (2009). The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase. Cancer res, Vol.69 (11), pp. 4716-4723.  show abstract

Banerjee, S. & Gore, M. (2009). The future of targeted therapies in ovarian cancer. Oncologist, Vol.14 (7), pp. 706-716.  show abstract

Smith, I.E. & Banerjee, S. (2009). The follow-up of women at high risk for breast cancer relapse. Breast, Vol.18 Suppl 3, pp. S74-S77.

Banerjee, S., Pancholi, S., A'hern, R., Ghazoui, Z., Smith, I.E., Dowsett, M. & Martin, L.-. (2008). The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer. Clin cancer res, Vol.14 (9), pp. 2656-2663.  show abstract

Pancholi, S., Lykkesfeldt, A.E., Hilmi, C., Banerjee, S., Leary, A., Drury, S., Johnston, S., Dowsett, M. & Martin, L.-. (2008). ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr relat cancer, Vol.15 (4), pp. 985-1002.  show abstract

Banerjee, S., Dowsett, M., Ashworth, A. & Martin, L.-. (2007). Mechanisms of disease: angiogenesis and the management of breast cancer. Nat clin pract oncol, Vol.4 (9), pp. 536-550.  show abstract

Banerjee, S., Reis-Filho, J.S., Ashley, S., Steele, D., Ashworth, A., Lakhani, S.R. & Smith, I.E. (2006). Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J clin pathol, Vol.59 (7), pp. 729-735.  show abstract

Banerjee, S., Reis, J.S., Ashley, S., Steele, D., Ashworth, A., Lakhani, S.R. & Smith, I.E. (2006). Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J clin pathol, Vol.59 (7), pp. 729-735.  show abstract

Lee, J.C., Banerjee, S. & King, D.M. (2005). Breast or chest? A diagnostic conundrum. British journal of radiology, Vol.78 (929), pp. 471-472.

Banerjee, S., Smith, I.E., Folkerd, L., Iqbal, J., Barker, P., Dowsett, M. & IMPACT trialists, (2005). Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. Ann oncol, Vol.16 (10), pp. 1632-1638.  show abstract

Parton, M., Maisey, N., Banerjee, S., Harper-Wynne, C., Sumpter, K., Ashley, S., Eisen, T. & Obrien, M. (2004). Gefitinib in patients with non-small cell lung cancer (NSCLC): The Royal Marsden experience. J clin oncol, Vol.22 (14_suppl), p. 7099.  show abstract

George, A., Riddell, D., Seal, S., Talukdar, S., Mahamdallie, S., Ruark, E., Cloke, V., Slade, I., Kemp, Z., Gore, M., et al. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian Cancer Patients. Scientific reports, .  show abstract

Yang, Y., Wu, L., Shu, X., Lu, Y., Shu, X.-., Cai, Q., Beeghly-Fadiel, A., Li, B., Ye, F., Berchuck, A., et al. Genetic data from nearly 63,000 women of European descent predicts DNA methylation biomarkers and epithelial ovarian cancer risk. Cancer research, , pp. canres.2726.2018-canres.2726.2018.


Conferences

Oaknin, A., Moore, K., Colombo, N., Scambia, G., Kim, B.-., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G.S., et al. (2019). Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial, ANNALS OF ONCOLOGY, Vol.30, p.405.

Glasspool, R., Lewsley, L.-., Daniele, G., Cook, A.D., Yanaihara, N., Tinker, A., Kristensen, G., Ottevanger, P., Aravantinos, G., Boere, I.A., et al. (2018). Progression free survival as a surrogate endpoint for overall survival in first-line therapy of advanced ovarian cancer: A Gynecologic Cancer InterGroup (GCIG) individual patient-level meta-analysis, BRITISH JOURNAL OF CANCER, Vol.119 (11), pp.47-48.

Aguilar, C.M., Vroobel, K., Lalondrelle, S., Taylor, A., Nobbenhuis, M., Attygalle, A., Banerjee, S. & George, A. (2018). Prevalence and clinical implications of mismatch repair (MMR) deficiency in unselected endometrial cancer (EC) patients, ANNALS OF ONCOLOGY, Vol.29.

Morgan, R.D., Jayson, G.C., Banerjee, S., Clamp, A.R., Lyon, A.R., Ryder, W.D., Hutson, R., Mescallado, N., Aguilar, C.O., Taylor, S., et al. (2018). A phase Ib and randomised phase II trial of pazopanib with or without fosbretabulin in advanced recurrent ovarian cancer, ANNALS OF ONCOLOGY, Vol.29, p.342.

Lorusso, D., Coleman, R.L., Oza, A.M., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J.I., Clamp, A.R., Scambia, G., et al. (2018). Subgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: Effect of prior chemotherapy regimens in ARIEL3, ANNALS OF ONCOLOGY, Vol.29.

Korach, J., Freyer, G., Banerjee, S., Asher, R., Cosin, J., Oza, A.M., Poveda, A.M., Di Napoli, M., Scott, C., Lapresa, M., et al. (2018). Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial, ANNALS OF ONCOLOGY, Vol.29.

Moore, K.N., Colombo, N., Scambia, G., Kim, B.-., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G.S., et al. (2018). Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial, ANNALS OF ONCOLOGY, Vol.29, p.727.

Aguilar, C.M., Vroobel, K., Attygalle, A., Lalondrelle, S., Taylor, A., Nobbenhuis, M., Banerjee, S. & George, A. (2018). MMR deficiency(d) in an unselected cohort of endometrial cancer (EC) patients, the Royal Marsden experience, ANNALS OF ONCOLOGY, Vol.29.

Aguilar, C.M., Dumas, L., Davies, E., Gore, M., George, A. & Banerjee, S. (2018). Olaparib maintenance treatment, the Royal Marsden experience, ANNALS OF ONCOLOGY, Vol.29.

Friedlander, M., Moore, K., Colombo, N., Scambia, G., Kim, B.-., Oaknin, A., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G.S., et al. (2018). Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial, ANNALS OF ONCOLOGY, Vol.29.

Oza, A.M., Matulonis, U.A., Malander, S., Sehouli, J., del Campo, J.M., Berthon-Rigaud, D., Banerjee, S., Scambia, G., Berek, J.S., Lund, B., et al. (2017). Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA Trial, ANNALS OF ONCOLOGY, Vol.28.

Moore, K.N., Vergote, I., Oaknin, A., Colombo, N., Banerjee, S., Oza, A.M., Pautier, P., Kelly, C.M., Malek, K. & Birrer, M.J., et al. (2017). FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer, ANNALS OF ONCOLOGY, Vol.28.

Ledermann, J., Sehouli, J., Zurawski, B., Raspagliesi, F., De Giorgi, U., Banerjee, S., Arranz Arija, J., Romeo Marin, M., Lisyanskaya, A., Poka, R.L., et al. (2017). A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma, ANNALS OF ONCOLOGY, Vol.28.

Fabbro, M., Moore, K.N., Dorum, A., Tinker, A.V., Mahner, S., Bover, I., Banerjee, S., Tognon, G., Goffin, F., Shapira-Frommer, R., et al. (2017). Safety and Efficacy of Niraparib in Elderly Patients (Pts) with Recurrent Ovarian Cancer (OC), ANNALS OF ONCOLOGY, Vol.28.

Boussios, S., Glaessgen, D., Okines, A., Lalondrelle, S., Taylor, A., McLachlan, J., Gore, M., Kaye, S. & Banerjee, S. (2015). 2767 Second line systemic treatment options for recurrent/advanced cervical cancer - The Royal Marsden experience, European Journal of Cancer, Vol.51, p.S553.

Banerjee, S., Ledermann, J., Matulonis, U., Molife, L.R., Friedlander, M., Fielding, A., Robertson, J.D., Spencer, S., McMurtry, E. & Kaye, S., et al. (2015). 2759 Management of nausea and vomiting during treatment with the capsule (CAP) and tablet (TAB) formulations of the PARP inhibitor olaparib, European Journal of Cancer, Vol.51, p.S550.

Kolomainen, D., Butler, J., Barton, D.P., Taylor, A., Stanley, K., Gore, M. & Banerjee, S. (2015). 2758 Is there a survival benefit for patients who receive post-operative adjuvant chemotherapy following secondary cytoreductive surgery (SCRS) for recurrent epithelial ovarian cancer (EOC)?, European Journal of Cancer, Vol.51, p.S550.

Nicum, S., Boyle, L., Strauss, V., Gourley, C., Hall, M., Montes, A., Abraham, J., Clamp, A., Kennedy, R., Banerjee, S., et al. (2015). 2761 Phase II clinical trial of 6 mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours, European Journal of Cancer, Vol.51, p.S551.

Rafii, S., Gourley, C., Ang, J.E., Kumar, R., Geuna, E., Rye, T., Ashcroft, L., Powell, B., Shapira-Frommer, R., Friedlander, M., et al. (2015). What clinical factors influence advanced BRCA1/2 mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment?, Journal of Clinical Oncology, Vol.33 (15_suppl), p.5546.

Migali, C., Lima, J.P., George, A., Della Pepa, C., Kaye, S.B., Gore, M.E. & Banerjee, S. (2014). OVARIAN CARCINOSARCOMA MANAGEMENT: A RETROSPECTIVE ANALYSIS OF THE ROYAL MARSDEN EXPERIENCE, ANNALS OF ONCOLOGY, Vol.25.

George, A., Tunariu, N., Della Pepa, C., Migali, C., Gore, M., Kaye, S.B. & Banerjee, S.B. (2013). Response to tamoxifen (T) and letrozole (L) in patients with relapsed high-grade ovarian carcinoma - the Royal Marsden experience, EUROPEAN JOURNAL OF CANCER, Vol.49, p.S732.

McNeish, I.A., Ledermann, J.A., Webber, L.C., James, L.E., Kaye, S.B., Rustin, G.J., Hall, G., Clamp, A., Earl, H.M., Banerjee, S.N., et al. (2013). A randomized placebo-controlled trial of saracatinib (AZD0530) plus weekly paclitaxel in platinum-resistant ovarian, fallopian-tube, or primary peritoneal cancer (SaPPrOC), JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (15).

George, A., Tunariu, N., Wilkinson, N., Gupta, S., Gore, M.E., Kaye, S.B. & Banerjee, S. (2012). EFFICACY OF PLATINUM PLUS GEMCITABINE (G) IN PLATINUM-RESISTANT (R) COMPARED TO PLATINUM-SENSITIVE (S) OVARIAN CANCER: THE ROYAL MARSDEN EXPERIENCE, ANNALS OF ONCOLOGY, Vol.23, p.320.

Miller, R., Brough, R., Bajrami, I., Kaye, S., Banerjee, S., Lord, C. & Ashworth, A. (2012). Functional Profiling of Clear Cell Ovarian Cancer, EUROPEAN JOURNAL OF CANCER, Vol.48, p.33.

Molife, L.R., Mateo, J., McGoldrick, T., Krebs, M., Drew, Y., Banerjee, S.N., Nicum, S., Ranson, M., Rustin, G.J., Sessa, C., et al. (2012). Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations, JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Penson, R.T., Moore, K.N., Fleming, G.F., Braly, P.S., Schimp, V.L., Nguyen, H., Matulonis, U., Banerjee, S.N., Haluska, P., Gore, M.E., et al. (2012). A phase II, open-label, multicenter study of IMC-1121B (ramucirumab; RAM) monotherapy in the treatment of persistent or recurrent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal (PPC) carcinoma (CP12-0711/NCT00721162)., JOURNAL OF CLINICAL ONCOLOGY, Vol.30 (15).

Banerjee, S.N., Zvelebil, M., Furet, P., Mueller-Vieira, U., Dowsett, M., Evans, D. & Martin, L. (2009). IN VITRO AND IN VIVO STUDIES REVEAL THAT THE VEGF-R INHIBITOR PTK787/ZK222584 IS A COMPETITIVE AROMATASE INHIBITOR, Presented at IMPAKT Breast Cancer Conference 2009, Brussels, BELGIUM. ANNALS OF ONCOLOGY, Vol.20, p.61.

Banerjee, S.N., Thornhill, A., Evans, D.B., Littlewood-Evans, A.J., Dowsett, M. & Martin, L.A. (2007). The VEGF-R inhibitor PTK787/ZK222584 (PTK/ZK) also inhibits aromatase: preclinical studies of PTK/ZK in combination with endocrine therapy, Presented at 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX. BREAST CANCER RESEARCH AND TREATMENT, Vol.106, p.S8.

Banerjee, S.N., Pancholi, S., A'Hern, R.P., Smith, I.E., Dowsett, M. & Martin, L.A. (2006). The effect of neo-adjuvant tamoxifen or anastrozole on circulating VEGF levels., Presented at 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX. BREAST CANCER RESEARCH AND TREATMENT, Vol.100, p.S242.

Banerjee, S.N., Reis, J.S., Ashley, S., Steele, D., Ashworth, A., Lakhani, S. & Smith, I.E. (2005). Basal-like breast carcinomas: clinical outcome with chemotherapy., Presented at 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX. BREAST CANCER RESEARCH AND TREATMENT, Vol.94, p.S125.

Parton, M., Maisey, N., Banerjee, S., Harper-Wynne, C., Sumpter, K., Ashley, S., Eisen, T. & Obrien, M. (2004). Gefitinib in patients with non-small cell lung cancer (NSCLC): The Royal Marsden experience., JOURNAL OF CLINICAL ONCOLOGY, Vol.22 (14), p.641S.

In this section

Research overview Research projects Publications